PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

INTRODUCTION: Until recently, systemic chemotherapy was the only option for treating bladder cancer and outcomes remained dismal. After a long gap of no progress for 40 years, immuno-therapy with checkpoint inhibitors (PDL1 and PD1) has revolutionized the treatment paradigm of bladder cancer, with f...

Descripción completa

Detalles Bibliográficos
Autores principales: Stenehjem, David D, Tran, Dao, Nkrumah, Michael A, Gupta, Shilpa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157986/
https://www.ncbi.nlm.nih.gov/pubmed/30275703
http://dx.doi.org/10.2147/OTT.S135157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157986/
https://www.ncbi.nlm.nih.gov/pubmed/30275703
http://dx.doi.org/10.2147/OTT.S135157

Ejemplares similares